• +1-646-491-9876
    • +91-20-67278686

    Search

    Oligodendroglioma - Pipeline Review, H1 2017

    Oligodendroglioma - Pipeline Review, H1 2017

    • Report Code ID: RW0001767479
    • Category Pharmaceuticals
    • No. of Pages 130
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Oligodendroglioma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma - Pipeline Review, H1 2017, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape.

    Oligodendroglioma is a type of glioma (primary glial brain tumor) . They often contain mineral deposits (called calcifications) , areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy surgery and radiation therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Oligodendroglioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Oligodendroglioma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Oligodendroglioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 5 and 10 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

    Oligodendroglioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Oligodendroglioma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Oligodendroglioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Oligodendroglioma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Oligodendroglioma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Oligodendroglioma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Oligodendroglioma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Oligodendroglioma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Oligodendroglioma - Overview
    Oligodendroglioma - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Oligodendroglioma - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Oligodendroglioma - Companies Involved in Therapeutics Development
    AngioChem Inc
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Cavion LLC
    Celldex Therapeutics Inc
    F. Hoffmann-La Roche Ltd
    Ipsen SA
    Millennium Pharmaceuticals Inc
    Northwest Biotherapeutics Inc
    Novartis AG
    Pfizer Inc
    Tocagen Inc
    Oligodendroglioma - Drug Profiles
    afatinib dimaleate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    alisertib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bevacizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CDX-1401 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for Gliomas - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dasatinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DCVax-L - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    flucytosine + TBio-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    flucytosine ER + vocimagene amiretrorepvec - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    irinotecan hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    irinotecan hydrochloride + TBio-02 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mibefradil dihydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nilotinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    p28 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    paclitaxel trevatide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    palbociclib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TBX.OncV NSC - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Oligodendroglioma - Dormant Projects
    Oligodendroglioma - Discontinued Products
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Oligodendroglioma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Oligodendroglioma - Pipeline by AngioChem Inc, H1 2017
    Oligodendroglioma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Oligodendroglioma - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Oligodendroglioma - Pipeline by Cavion LLC, H1 2017
    Oligodendroglioma - Pipeline by Celldex Therapeutics Inc, H1 2017
    Oligodendroglioma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Oligodendroglioma - Pipeline by Ipsen SA, H1 2017
    Oligodendroglioma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Oligodendroglioma - Pipeline by Northwest Biotherapeutics Inc, H1 2017
    Oligodendroglioma - Pipeline by Novartis AG, H1 2017
    Oligodendroglioma - Pipeline by Pfizer Inc, H1 2017
    Oligodendroglioma - Pipeline by Tocagen Inc, H1 2017
    Oligodendroglioma - Dormant Projects, H1 2017
    Oligodendroglioma - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Oligodendroglioma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AngioChem Inc
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Cavion LLC
    Celldex Therapeutics Inc
    F. Hoffmann-La Roche Ltd
    Ipsen SA
    Millennium Pharmaceuticals Inc
    Northwest Biotherapeutics Inc
    Novartis AG
    Pfizer Inc
    Tocagen Inc

    Request for Sample

    Report Url http://www.reportsweb.com//oligodendroglioma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//oligodendroglioma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//oligodendroglioma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments